Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Non-Small Cell Lung Cancer: Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Non-Small Cell Lung Cancer. According...
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Gastric Cancer: Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Gastric Cancer. According to GlobalData,...
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Head And Neck Cancer: Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Head And Neck Cancer. According...